Literature DB >> 33446784

Increased VEGF-A in solid type of lung adenocarcinoma reduces the patients' survival.

Woon Yong Jung1, Kyueng-Whan Min2, Young Ha Oh1.   

Abstract

The histological classification of lung adenocarcinoma includes 5 types: lepidic, acinar, papillary, micropapillary and solid. The complex gene interactions and anticancer immune response of these types are not well known. The aim of this study was to reveal the survival rates, genetic alterations and immune activities of the five histological types and provide treatment strategies. This study reviewed the histological findings of 517 patients with lung adenocarcinoma from The Cancer Genome Atlas (TCGA) database and classified them into five types. We performed gene set enrichment analysis (GSEA) and survival analysis according to the different types. We found six oncogenic gene sets that were higher in lung adenocarcinoma than in normal tissues. In the survival analysis of each type, the acinar type had a favorable prognosis, and the solid subtype had an unfavorable prognosis; however, the survival differences between the other types were not significant. Our study focused on the solid type, which had the poorest prognosis. The solid type was related to adaptive immune resistance associated with elevated CD8 T cells and high CD274 (encoding PD-L1) expression. In the pathway analyses, the solid type was significantly related to high vascular endothelial growth factor (VEGF)-A expression, reflecting tumor angiogenesis. Non-necrosis/low immune response affected by high VEGF-A was associated with worse prognosis. The solid type associated with high VEGF-A expression may contribute to the development of therapeutic strategies for lung adenocarcinoma.

Entities:  

Year:  2021        PMID: 33446784      PMCID: PMC7809025          DOI: 10.1038/s41598-020-79907-6

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  48 in total

Review 1.  Classifying Cancers Based on T-cell Infiltration and PD-L1.

Authors:  Michele W L Teng; Shin Foong Ngiow; Antoni Ribas; Mark J Smyth
Journal:  Cancer Res       Date:  2015-06-01       Impact factor: 12.701

2.  The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification.

Authors:  William D Travis; Elisabeth Brambilla; Andrew G Nicholson; Yasushi Yatabe; John H M Austin; Mary Beth Beasley; Lucian R Chirieac; Sanja Dacic; Edwina Duhig; Douglas B Flieder; Kim Geisinger; Fred R Hirsch; Yuichi Ishikawa; Keith M Kerr; Masayuki Noguchi; Giuseppe Pelosi; Charles A Powell; Ming Sound Tsao; Ignacio Wistuba
Journal:  J Thorac Oncol       Date:  2015-09       Impact factor: 15.609

3.  Bronchioloalveolar carcinoma and lung adenocarcinoma: the clinical importance and research relevance of the 2004 World Health Organization pathologic criteria.

Authors:  William D Travis; Kavita Garg; Wilbur A Franklin; Ignacio I Wistuba; Bradley Sabloff; Masayuki Noguchi; Ryutaro Kakinuma; Maureen Zakowski; Michelle Ginsberg; Robert Padera; Francine Jacobson; Bruce E Johnson; Fred Hirsch; Elizabeth Brambilla; Douglas B Flieder; Kim R Geisinger; Frederik Thunnissen; Keith Kerr; David Yankelevitz; Teri J Franks; Jeffrey R Galvin; Douglas W Henderson; Andrew G Nicholson; Philip S Hasleton; Victor Roggli; Ming-Sound Tsao; Federico Cappuzzo; Madeline Vazquez
Journal:  J Thorac Oncol       Date:  2006-11       Impact factor: 15.609

4.  Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.

Authors:  Aravind Subramanian; Pablo Tamayo; Vamsi K Mootha; Sayan Mukherjee; Benjamin L Ebert; Michael A Gillette; Amanda Paulovich; Scott L Pomeroy; Todd R Golub; Eric S Lander; Jill P Mesirov
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-30       Impact factor: 11.205

5.  Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases.

Authors:  Akihiko Yoshizawa; Noriko Motoi; Gregory J Riely; Cami S Sima; William L Gerald; Mark G Kris; Bernard J Park; Valerie W Rusch; William D Travis
Journal:  Mod Pathol       Date:  2011-01-21       Impact factor: 7.842

6.  Histologic features associated with metastatic potential in invasive adenocarcinomas of the lung.

Authors:  Lauren Xu; Fabio Tavora; Allen Burke
Journal:  Am J Surg Pathol       Date:  2013-07       Impact factor: 6.394

7.  Lung adenocarcinoma: modification of the 2004 WHO mixed subtype to include the major histologic subtype suggests correlations between papillary and micropapillary adenocarcinoma subtypes, EGFR mutations and gene expression analysis.

Authors:  Noriko Motoi; Janos Szoke; Gregory J Riely; Venkatraman E Seshan; Mark G Kris; Valerie W Rusch; William L Gerald; William D Travis
Journal:  Am J Surg Pathol       Date:  2008-06       Impact factor: 6.394

8.  Oncogenic Signaling Pathways in The Cancer Genome Atlas.

Authors:  Francisco Sanchez-Vega; Marco Mina; Joshua Armenia; Walid K Chatila; Augustin Luna; Konnor C La; Sofia Dimitriadoy; David L Liu; Havish S Kantheti; Sadegh Saghafinia; Debyani Chakravarty; Foysal Daian; Qingsong Gao; Matthew H Bailey; Wen-Wei Liang; Steven M Foltz; Ilya Shmulevich; Li Ding; Zachary Heins; Angelica Ochoa; Benjamin Gross; Jianjiong Gao; Hongxin Zhang; Ritika Kundra; Cyriac Kandoth; Istemi Bahceci; Leonard Dervishi; Ugur Dogrusoz; Wanding Zhou; Hui Shen; Peter W Laird; Gregory P Way; Casey S Greene; Han Liang; Yonghong Xiao; Chen Wang; Antonio Iavarone; Alice H Berger; Trever G Bivona; Alexander J Lazar; Gary D Hammer; Thomas Giordano; Lawrence N Kwong; Grant McArthur; Chenfei Huang; Aaron D Tward; Mitchell J Frederick; Frank McCormick; Matthew Meyerson; Eliezer M Van Allen; Andrew D Cherniack; Giovanni Ciriello; Chris Sander; Nikolaus Schultz
Journal:  Cell       Date:  2018-04-05       Impact factor: 41.582

9.  Autocrine VEGF signaling promotes cell proliferation through a PLC-dependent pathway and modulates Apatinib treatment efficacy in gastric cancer.

Authors:  Yi Lin; Ertao Zhai; Bing Liao; Lixia Xu; Xinhua Zhang; Sui Peng; Yulong He; Shirong Cai; Zhirong Zeng; Minhu Chen
Journal:  Oncotarget       Date:  2017-02-14

10.  CluePedia Cytoscape plugin: pathway insights using integrated experimental and in silico data.

Authors:  Gabriela Bindea; Jérôme Galon; Bernhard Mlecnik
Journal:  Bioinformatics       Date:  2013-01-16       Impact factor: 6.937

View more
  5 in total

Review 1.  VEGF/VEGFR-Targeted Therapy and Immunotherapy in Non-small Cell Lung Cancer: Targeting the Tumor Microenvironment.

Authors:  Yueshui Zhao; Sipeng Guo; Jian Deng; Jing Shen; Fukuan Du; Xu Wu; Yu Chen; Mingxing Li; Meijuan Chen; Xiaobing Li; Wanping Li; Li Gu; Yuhong Sun; Qinglian Wen; Jing Li; Zhangang Xiao
Journal:  Int J Biol Sci       Date:  2022-05-29       Impact factor: 10.750

2.  Iloprost requires the Frizzled-9 receptor to prevent lung cancer.

Authors:  Kayla Sompel; Lori D Dwyer-Nield; Alex J Smith; Alamelu Elango; Don S Backos; Bicheng Zhang; James Gross; Kristina Ternyak; Jennifer L Matsuda; Katrina Kopf; Robert L Keith; Meredith A Tennis
Journal:  iScience       Date:  2022-05-23

Review 3.  Correlation between the Expression of VEGF and Ki67 and Lymph Node Metastasis in Non-small-Cell Lung Cancer: A Systematic Review and Meta-Analysis.

Authors:  Dong Wei; Yunchao Xin; Yu Rong; Yanbing Hao
Journal:  Evid Based Complement Alternat Med       Date:  2022-06-28       Impact factor: 2.650

4.  Baohuoside I Inhibits Tumor Angiogenesis in Multiple Myeloma via the Peroxisome Proliferator-Activated Receptor γ/Vascular Endothelial Growth Factor Signaling Pathway.

Authors:  Ying Chen; Lina Zhang; Xiaoyan Zang; Xuxing Shen; Jianyong Li; Lijuan Chen
Journal:  Front Pharmacol       Date:  2022-03-07       Impact factor: 5.810

5.  Palmar Fasciitis and Polyarthritis Syndrome Associated with Lung Adenocarcinoma.

Authors:  Hisatoshi Okumura; Hidetaka Ishino; Daisuke Yokoi; Masami Matsumura
Journal:  Intern Med       Date:  2021-12-28       Impact factor: 1.282

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.